UBS Group’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-45,400
Closed -$1.02M 9642
2024
Q2
$1.02M Buy
+45,400
New +$1.01M ﹤0.01% 4409
2024
Q1
Sell
-49,900
Closed -$1.2M 9491
2023
Q4
$1.2M Hold
49,900
﹤0.01% 4340
2023
Q3
$1.09M Sell
49,900
-53,300
-52% -$1.11M ﹤0.01% 3992
2023
Q2
$1.97M Buy
103,200
+26,600
+35% +$513K ﹤0.01% 3540
2023
Q1
$1.49M Buy
+76,600
New +$1.33M ﹤0.01% 3731
2017
Q2
Sell
-1,602,400
Closed -$34.7M 7754
2017
Q1
$34.7M Buy
1,602,400
+1,102,400
+220% +$22.4M 0.02% 710
2016
Q4
$7.46M Buy
+500,000
New +$7.21M ﹤0.01% 1743
2015
Q2
Sell
-58,100
Closed -$149K 8586
2015
Q1
$149K Sell
58,100
-17,200
-23% -$39.9K ﹤0.01% 5116
2014
Q4
$108K Buy
+75,300
New +$117K ﹤0.01% 5626

Other funds holding EXEL

UBS Group's EXEL Position: Q1 2026 in Review

UBS Group reduced its Exelixis (EXEL) stake by 36% in Q1 2026, selling an estimated $57.1M and leaving 2,393,513 shares worth $103M. The position accounts for 0.02% of the portfolio, ranked #1029.

UBS Group first reported a position in EXEL in Q4 2014 and has held it in 46 quarters since. The position peaked at $163M in Q4 2025. 695 funds tracked by Wall St. Rank hold EXEL as of Q1 2026.

  • UBS Group held 2,393,513 shares of Exelixis worth $103M as of Q1 2026.
  • UBS Group sold 1,328,821 Exelixis shares in Q1 2026, an estimated $57.1M.
  • Exelixis made up 0.02% of UBS Group's portfolio in Q1 2026, its #1029 holding.
  • UBS Group first reported a position in Exelixis in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Exelixis position peaked at $163M in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Exelixis as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.